Ceritinib is a lung cancer treatment that inhibits the Anaplastic Lymphoma Kinase (ALK). ALK is a protein involved in cell signaling and growth regulation. Initially discovered in anaplastic large cell lymphoma, ALK has since been found to play critical roles in various cancers and neurodevelopmental processes. Targeted therapies that inhibit ALK have revolutionized treatment for ALK-positive cancers, improving outcomes significantly. Research continues to explore ALK’s intricate mechanisms and its potential as a therapeutic target beyond oncology, highlighting its broad biological importance. In this study, Ceritinib-drug loaded nanostructured lipid carriers were produced using a modified homogenization process by increasing number of homogenisation cycles followed by probe sonication. A central composite design was utilised to investigate the effect of liquid lipid (A), emulsifier (B), and co-surfactant (C) concentrations on particle size (Response 1) and entrapment efficiency (Response 2). The specific impacts of these parameters on particle size and entrapment efficiency were shown in response surfaces, using Derringer’s desirability technique. Formulation 8 with 0.1% Capmul, 0.15% egg lecithin, and 0.37% poloxamer 188 was subjected to further evaluation as it had minimal particle size and maximum entrapment efficiency. The SEM analysis was performed to confirm the size of the particle which was within the nano range. The in vitro studies indicated the maximum drug release (84.6%±2.3% in 12 hours) from that of the marketed formulation (54.2%±2.5% in 12 hours). After 90 days of stability testing, there was no significant variation (p < 0.05) in parameters like particle size and entrapment efficiency.
Janakiraman K, Madhav KV, Padavala SKC, Pamujula NH. Enhanced bioavailability through quality by design optimization of ceritinib nanostructured lipid carriers: Formulation, characterization, and stability evaluation. J Appl Pharm Sci. 2024. Online First. http://doi.org/10.7324/JAPS.2024.188653
1. Chennuru R, Koya RT, Kommavarapu P, Narasayya SV, Muthudoss P, Vishweshwar P, et al. In situ metastable form: a route for the generation of hydrate and anhydrous forms of ceritinib. Cryst Growth Des .2017;17(12):6341–52. doi: http://dx.doi.org/10.1021/acs.cgd.7b01027
2. Awasthi A, Dheeraj HM, Birangal S, Pai A, Pai G, Sathyanarayana MB. Fabrication of ceritinib cocrystals with improved solubility: preparation, solid-state characterization, solubility studies, and molecular docking studies. Rasayan J Chem. 2022;14(02):905–13.
3. Fda.gov. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ceritinib-advanced-anaplastic-lymphoma-kinase-positive-lung-cancer.
4. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54:S131–55. doi: http://dx.doi.org/10.1016/s0169-409x(02)00118-7
5. Date AA, Nagarsenker MS. Design and evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) for cefpodoxime proxetil. Int J Pharm. 2007;329(1–2):166–72. doi: http://dx.doi.org/10.1016/j.ijpharm.2006.08.038
6. Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and ‘self-microemulsifying’ drug delivery systems. Eur J Pharm Sci. 2000;11:S93–8. doi: http://dx.doi.org/10.1016/s0928-0987(00)00167-6
7. Attama AA, Müller-Goymann CC. Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN). Int J Pharm. 2008;355(1–2):249–56.
8. Hu FQ, Yuan H. Zhang Y. A novel chitosan oligosaccharide-stearic acid micelles for gene delivery: properties and in vitro transfection studies. Int J Pharm. 2010;395(1–2):248–56.
9. Souto EB, Müller RH. Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. Handb Exp Pharmacol. 2010;(197):115–41. doi: http://dx.doi.org/10.1007/978-3-642-00477-3_4
10. Lohan S, Sharma S, Murthy RR. Formulation and evaluation of solid lipid nanoparticles of quetiapine fumarate and quetiapine hemifumarate for brain delivery in rat model. Pharm Nanotechnol. 2013;1:239–47.
11. Rajendra C, Harish P, Jain AK, Himesh HH, Saraogi GK. Preparation and evaluation of the self emulsifying drug delivery system containing atorvastatin HMG-COA inhibiter. Int J Pharm Pharm Sci. 2011;3:147–52.
12. Nekkanti V, Wang Z, Betageri GV. Pharmacokinetic evaluation of improved oral bioavailability of valsartan: proliposomes versus self-nanoemulsifying drug delivery system. AAPS PharmSciTech. 2016;17(4):851–62. doi: http://dx.doi.org/10.1208/s12249-015-0388-8
13. Ke Z, Hou X, Jia XB. Design and optimization of selfnanoemulsifying drug delivery systems for improved bioavailability of cyclovirobuxine D. Drug Des Devel Ther. 2016;10:2049–60.
14. Potu AR, Pujari N, Burra S, Veerareddy PR. Formulation and evaluation of buccoadhesive quetiapine fumarate tablets. Braz J Pharm Sci. 2012;48(2):335–45. doi: http://dx.doi.org/10.1590/s1984-82502012000200017
15. Fang CL, Al-Suwayeh SA, Fang JY. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat Nanotechnol. 2013;7(1):41–55. doi: http://dx.doi.org/10.2174/187221013804484827
16. Shah P, Desai M, Shah D, Sarolia J, Gandhi J. Formulation and evaluation of ezetimibe loaded solid lipid nanoparticles. Indo Am J Pharm Res. 2017;7:661–73.
17. Mishra B, Mittal P, Vardhan H, Ajmal G, Bonde GV, Kapoor R, et al. Genistein-loaded nanostructured lipid carriers for intravenous administration: a quality by design-based approach. Int Res J Pharm. 2019;10(1):119–34.
18. Gadad AP, Tigadi SG, Dandagi PM, Mastiholimath VS, Bolmal UB. Rosuvastatin loaded nanostructured lipid carrier: for enhancement of oral bioavailability. Ind J Pharm Educ. 2016;50(4):605–11. doi: http://dx.doi.org/10.5530/ijper.50.4.13
19. Shah B, Khunt D, Misra M, Padh H. Non-invasive intranasal delivery of quetiapine fumarate loaded microemulsion for brain targeting: formulation, physicochemical and pharmacokinetic consideration. Eur J Pharm Sci. 2016;91:196–207. doi: http://dx.doi.org/10.1016/j.ejps.2016.05.008
20. Müller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs—a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol. 2004;113(1–3):151–70.
Year
Month